Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan

Clinical trial NCT00742105 · TERMINATED

Trial details

NCT number: NCT00742105
Sponsor: Novartis Pharmaceuticals
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Cancer Solid Tumor Advanced Solid Tumor

Start date: 2008-11-17
Primary completion: 2009-12-22
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.